NEUMORA THERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
NEUMORA THERAPEUTICS, INC. (NMRA) reported Basic Shares Outstanding (Weighted Average) of 185.16 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 185.16M shares, a 14.52% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 179.87M shares, a 11.41% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 168.57M shares, a 4.71% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 161.84M shares, a 1.42% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 163.39M shares, a 2.52% increase from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 159.38M shares, a 145.12% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 65.02M shares, a 138.99% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 27.21M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 185.16M shares 10-Q · filed 2026-08-14 | 182.50M shares 10-Q · filed 2026-08-14 | 177.87M shares derived: average of 3 quarters · filed 2026-08-14 | 173.86M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 179.87M shares 10-Q · filed 2026-05-07 | 174.22M shares derived: average of 2 quarters · filed 2026-05-07 | 170.09M shares derived: average of 3 quarters · filed 2026-05-07 | 167.99M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | 168.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 165.21M shares derived: average of 2 quarters · filed 2026-03-30 | 164.03M shares derived: average of 3 quarters · filed 2026-08-14 | 163.39M shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 161.84M shares 10-Q · filed 2025-11-06 | 161.76M shares derived: average of 2 quarters · filed 2026-08-14 | 161.66M shares 10-Q · filed 2025-11-06 | 161.49M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | 161.69M shares 10-Q · filed 2026-08-14 | 161.57M shares 10-Q · filed 2026-08-14 | 161.38M shares derived: average of 3 quarters · filed 2026-08-14 | 160.93M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | 161.45M shares 10-Q · filed 2026-05-07 | 161.22M shares derived: average of 2 quarters · filed 2026-05-07 | 160.67M shares derived: average of 3 quarters · filed 2026-05-07 | 160.25M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 161.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 160.29M shares derived: average of 2 quarters · filed 2026-03-30 | 159.85M shares derived: average of 3 quarters · filed 2026-03-30 | 159.38M shares 10-K · filed 2026-03-30 |
| 2024-09-30 | 159.58M shares 10-Q · filed 2025-11-06 | 159.28M shares derived: average of 2 quarters · filed 2025-11-06 | 158.84M shares 10-Q · filed 2025-11-06 | 157.58M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 158.98M shares 10-Q · filed 2025-08-06 | 158.46M shares 10-Q · filed 2025-08-06 | 156.91M shares derived: average of 3 quarters · filed 2025-08-06 | 129.35M shares derived: average of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | 157.94M shares 10-Q · filed 2025-05-12 | 155.87M shares derived: average of 2 quarters · filed 2025-05-12 | 119.48M shares derived: average of 3 quarters · filed 2025-05-12 | 97.14M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 153.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 100.25M shares derived: average of 2 quarters · filed 2025-03-03 | 76.87M shares derived: average of 3 quarters · filed 2025-03-03 | 65.02M shares 10-K · filed 2025-03-03 |
| 2023-09-30 | 46.69M shares 10-Q · filed 2024-11-12 | 38.41M shares derived: average of 2 quarters · filed 2024-11-12 | 35.43M shares 10-Q · filed 2024-11-12 | 33.60M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | 30.13M shares 10-Q · filed 2024-08-06 | 29.70M shares 10-Q · filed 2024-08-06 | 29.24M shares derived: average of 3 quarters · filed 2025-03-03 | 28.84M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | 29.28M shares 10-Q · filed 2024-05-07 | 28.79M shares derived: average of 2 quarters · filed 2025-03-03 | 28.41M shares derived: average of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | 28.30M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 27.98M shares derived: average of 2 quarters · filed 2025-03-03 | 27.21M shares 10-K · filed 2025-03-03 | |
| 2022-09-30 | 27.65M shares 10-Q · filed 2023-11-01 | 26.84M shares 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |